Very few Cannabis-Based Products for Medicinal Use are available via NHS prescription, there are currently only a handful of specific conditions with qualified CBPM treatments available. More traditional treatments options are likely to be explored before the use of CBPMs is considered, your specialist may be unaware of CBPM treatment options available.
| Sativex | THC & CBD Spray | Treatment for Moderate to Severe Spasticity in Multiple Sclerosis Patients |
| Epidiolex | CBD Isolate Oil | Treatment for Seizures Associated with Lennox-Gastaut & Dravet Syndromes in Paediatric Patients (with Clobazam) |
| Nabilone | Synthetic THC | Add-on Treatment for Intractable Nausea/Vomiting for Chemotherapy Patients |
To the best of our understanding there are currently few prescriptions written for the medicines listed above. Outside of the specific medicines and their relevant use-cases listed, there is currently no further NHS accessibility to CBPMs. In January 2023, the first private prescription was reimbursed via the NHS, many patients are currently examining the potentiality of utilising the same pathway - though no other patients are known to have been reimbursed by the NHS successfully to-date.
National Health-Service FAQ: Cannabis-Based Products for Medicinal Use
Guidance from National Institute for Health & Care Excellence: Cannabis-Based Products for Medicinal Use
There was a Medical Cannabis Access Bill being debated in parliament which could further CBPM access in the future though this appears to have stalled. If you're currently considering the viability of medical cannabis for your health-care, only private medical cannabis clinics will be able to offer access to CBPMs as otherwise listed on this website.
Further National Health-Service Information on